1991/09/15 by William Paul Skelton, Nadine Khouzam Skelton · 6 citations
Medicine · #Alzheimer's disease #Alzheimer's disease research and treatments #Anxiety #Cholinesterase and Neurodegenerative Diseases #Cognition #Dementia #Dementia and Cognitive Impairment Research #Depression (economics) #Disease #Medicine #Neuropsychology #Pathology #Psychiatry #Verbal fluency test
paper · doi:10.1080/00325481.1991.11701056
published in Postgraduate Medicine 90(4), 33-41 (Taylor & Francis)
crossref issued 1991/09/15 · crossref published 1991/09/15 · crossref published-print 1991/09/15 · openalex publication_date 1991/09/15 · crossref published-online 2016/05/17 · crossref created 2016/05/17 · openalex created_date 2016/06/24 · crossref deposited 2017/06/24 · crossref indexed 2026/07/31 · openalex updated_date 2026/07/31
Alzheimer's disease is a costly illness affecting large numbers of older Americans, and its prevalence is increasing. The major symptom of the condition is progressive forgetfulness. The course is variable, depending on which areas of the brain are affected earliest and most severely. In diagnosing Alzheimer's disease, it is important to rule out other types of dementia that may be treatable, as well as systemic and affective disorders and other brain diseases. The Mini-Mental State Examination and the category fluency test are often diagnostically useful. There is no evidence that any of the therapeutic agents studied so far are of much value, but pharmacologic agents can be useful in treating the depression, psychoses, and anxiety that may accompany cognitive decline. Patients cared for at home need a structured, orderly environment that has been modified for their safety.